Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients

The mPEBev is an anticancer regimen which combines a chemotherapy doublet, based on cisplatin and oral etoposide (mPE), with bevacizumab (mPEBev), a mAb targeting the vasculo-endothelial growth factor (VEGF). In previous studies, this regimen showed powerful anti-angiogenetic effects and significant...

Descripción completa

Detalles Bibliográficos
Autores principales: Martino, EC, Misso, G, Pastina, P, Costantini, S, Vanni, F, Gandolfo, C, Botta, C, Capone, F, Lombardi, A, Pirtoli, L, Tassone, P, Ulivieri, C, Tagliaferri, P, Cusi, MG, Caraglia, M, Correale, P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045963/
https://www.ncbi.nlm.nih.gov/pubmed/27752361
http://dx.doi.org/10.1038/cddiscovery.2016.25

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045963/
https://www.ncbi.nlm.nih.gov/pubmed/27752361
http://dx.doi.org/10.1038/cddiscovery.2016.25

Ejemplares similares